Get the Stockscreener App
24.94
0.64%
-0.16
Pre-market:
24.83
-0.11
-0.44%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $24.94, with a volume of 44.99M.
It is down -0.64% in the last 24 hours and down -14.65% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.10
Open:
$25.07
24h Volume:
44.99M
Relative Volume:
1.32
Market Cap:
$140.91B
Revenue:
$59.37B
Net Income/Loss:
$4.25B
P/E Ratio:
13.63
EPS:
1.83
Net Cash Flow:
$8.23B
1W Performance:
-6.66%
1M Performance:
-14.65%
6M Performance:
-12.58%
1Y Performance:
-16.81%
1-Day Range:
$24.65
$25.10
1-Week Range:
$24.48
$26.85
52-Week Range:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PFE | 24.94 | 140.91B | 59.37B | 4.25B | 8.23B | 1.83 |
| LLY | 753.41 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 105.27 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 153.11 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 167.76 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 97.44 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer elevates Chris Boshoff to top R&D role - pharmaphorum
Mitochondrial-Based Therapeutics Market Key Players Analysis - openPR
Zai Lab Partners with Pfizer to Commercialize Novel Antibiotic XACDURO in China | ZLAB Stock News - StockTitan
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia - Pharmaceutical Technology
Pfizer, Flynn Still Face Fines Over Epilepsy Drug Sale To NHS - Law360
Meta, Pfizer on DOL List of Upcoming Contractor Anti-Bias Audits - Bloomberg Law
Health Care Climbs as Obesity-Drug Makers ReboundHealth Care Roundup - Marketscreener.com
How Pfizer is trying to make U.S. healthcare easier to navigate - Fast Company
Pfizer Picks Boshoff To Head R&D, A Smooth Transition In An Uncertain Time - Citeline News & Insights
Pfizer (NYSE:PFE) Stock Price Down 0.6%Should You Sell? - MarketBeat
EC approval for Pfizer’s Hympavzi - The Pharma Letter
Pfizer promoted oncology chief Chris Boshoff to serve as CSO, R&D president - MM+M Online
Flagship reveals new agreements under Pfizer link-up - The Pharma Letter
Pzena Investment Management LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer, under pressure to change, names oncology head as new R&D chief - BioPharma Dive
Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief - GuruFocus.com
Pfizer names oncology head Chris Boshoff as R&D chief - Reuters
Pfizer Taps Cancer Chief to Lead Research, Find Hit Drugs - MSN
Pfizer Names New Chief Scientific Officer And President Of R&D - Contract Pharma
Company veteran named chief scientific officer at Pfizer - ShareCast
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO - BioSpace
Chris Boshoff takes on new role at Pfizer - The Pharma Letter
First Horizon Advisors Inc. Purchases 95,749 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer: Marketing authorization for Hympavzi in the EU - Marketscreener.com
Pfizer promotes oncology chief to lead R&D as activist Starboard circles - Financial Times
Pfizer: new Chief Scientific Officer on January 1 - Marketscreener.com
Pfizer bags EU okay for haemophilia drug Hympavzi - pharmaphorum
Pfizer names Chris Boshoff as new R&D chief starting 2025 - Investing.com
Pfizer names head of oncology as new R&D chief - Seeking Alpha
Pfizer names new chief scientific officer - baha news
Pfizer taps insider as chief science officer amid pressure from activist Starboard - MarketWatch
Pfizer Names New R&D Chief: Dr. Boshoff to Lead Scientific Innovation After 24 Drug Approvals | PFE Stock News - StockTitan
Flagship, Pfizer alliance yields two more startup deals - BioPharma Dive
Pfizer names Chris Boshoff as new R&D chief, WSJ reports - Marketscreener.com
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer - PR Newswire
Pfizer Names New R&D Chief - Yahoo! Voices
Is It Time to Sell Eli Lilly and Pfizer Stocks? - Yahoo! Voices
Pfizer's HYMPAVZI Wins EU Approval: First Weekly Treatment for Severe Hemophilia | PFE Stock News - StockTitan
StockNews.com Downgrades Pfizer (NYSE:PFE) to Buy - MarketBeat
Penicillin Drug Market: Comprehensive Analysis and Key Players-Pfizer, Inc., Novartis AG, Sanofi S.A - openPR
UK Patent Win Over GSK Boosts Pfizer in Global RSV Vaccine Fight - BioSpace
Pfizer Unit Can't Get $75M Left In Insider Trading Deal Fund - Law360
Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules - Reuters
Pfizer loses bid to recoup $75 million left over from SEC settlement - Marketscreener.com
Pfizer (NYSE:PFE) Trading Up 0.7%Here's What Happened - MarketBeat
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Yahoo Finance
Pfizer Inc. (NYSE:PFE) Holdings Lowered by PNC Financial Services Group Inc. - MarketBeat
Parnassus Investments LLC Increases Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Holdings Lowered by Banque Cantonale Vaudoise - MarketBeat
Pfizer (NYSE:PFE) stock falls 5.3% in past week as three-year earnings and shareholder returns continue downward trend - Yahoo Finance
Verity & Verity LLC Purchases 108,863 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.83%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):